Abstracts tagged "pulmonary fibrosis and scleroderma"

Abstract Number: 1711 • 2017 ACR/ARHP Annual Meeting
SIRT1 May Protect Against Systemic Sclerosis-Related Pulmonary Fibrosis By Decreasing Pro-Inflammatory and Pro-Fibrotic Processes
Haiyan Chu¹, Shuai Jiang², Qingmei Liu³, Feng Qian⁴, Xiaodong Zhou⁵, Maureen D. Mayes⁶, Li Jin⁷ and Jiucun Wang⁸, ¹MOE Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ³State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, Chile, ⁴Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, ⁵Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁶University of Texas McGovern Medical School, Houston, TX, ⁷State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ⁸State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, CN
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Sirtuin1 (SIRT1) is a deacetylase with known anti-inflammatory and anti-fibrotic…
Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Anna Hoffmann-Vold¹, Elizabeth R. Volkmann², Oyvind Midtvedt³, Torhild Garen³, Anders Heiervang Tennøe³, Trond Mogens Aalokken⁴, May Brit Lund⁵ and Øyvind Molberg³, ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Vivien Hsu¹, Virginia D. Steen² and PHAROS Investigators, ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Rheumatology, Georgetown University Medical Center, Washington, DC
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].